OVARIAN CANCER and US: INNO-206

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label INNO-206. Show all posts
Showing posts with label INNO-206. Show all posts

Monday, August 22, 2011

CytRx President and CEO Steven Kriegsman and CMO Dr. Daniel Levitt Discuss Company Advantages and Oncology Clinical Pipeline Attributes in OncLive Interview - MarketWatch (INNO-206)




Note: in research

"Previous studies have shown INNO-206 efficacy in tumor models of breast, ovarian, small cell lung cancer, renal cell cancer and pancreatic cancers. Additionally, a recently announced study showed that low doses of INNO-206 and doxorubicin combined achieved complete remission in aggressively growing in vivo ovarian cancer tumors. Several other chemotherapy agents have been attached to the linker used for INNO-206, including paclitaxel, camptothecin, cisplatin and methotrexate, and may be incorporated into future clinical development by the Company."